NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-HER-2 bispecific antibody KN026
An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anti-HER-2 bispecific antibody KN026 simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-HER2 heterodimeric antibody KN026
HER2 bispecific antibody KN026
Code name:KN 026
KN026
KN-026